Background The advent of value-based care, in which surgeons and hospitals accept more responsibility for clinical and financial results, has increased the focus on surgeon-and hospital-specific outcomes. However, methods to identify high-quality, low-cost surgeons are not well developed. Questions/purposes (1) Is there an association between surgeon THA volume and 90-day Centers for Medicare & Medicaid Services (CMS) Part A payments, readmissions, or mortality? (2) What proportion of THAs in the United States is performed by low-and high-volume surgeons? Methods We performed a retrospective analysis of the CMS Limited Data Set on all primary elective THAs performed in the United States (except Maryland) between January 2013 and June 2016 on patients insured by Medicare. This represented 409,844 THAs totaling more than USD 7.7 billion in direct CMS expenditures. Surgeons were divided into five groups based on annualized volume of CMS elective THAs over the study period. Using linear and logistic regression, we calculated and compared 90-day CMS Part A payments, readmissions, and mortality among the groups. For each episode, demographic information (age, sex, and race), geographic location, and Elixhauser comorbidities were calculated to control for major confounding factors in the regression. Results When compared with the highest volume group, each lower volume group had increased payments, increased readmission rates, and increased mortality rates in a stepwise fashion when controlling for patient-specific variables including Elixhauser comorbidity index, demographic information, region, and background trend. The lowest volume group resulted in 27.2% more CMS payments per case (p < 0.001; 95% confidence interval [CI], 26.6%-27.8%), had an increased readmission odds ratio (OR) of 1.8 (p < 0.001; 95% CI, 1.7-1.9), and an increased mortality OR of 4.7 (p < 0.001; 95% CI, 4.0-5.5) when compared with the highest volume group. There was also variation within volume groups: some lower volume surgeons had lower payments, readmissions, This work was conducted with support from Harvard Catalyst, The
and mortality than some higher volume surgeons despite the general trend. In terms of CMS volume, surgeons who were at least moderate volume (11+ annual cases) performed 78% of THAs and represented 26% of operating surgeons. The low-and lowest volume surgeons (10 or fewer annual cases) performed only 22% of THAs in the United States while representing 74% of unique operating surgeons. Conclusions There is a strong association between a surgeon's Medicare volume and lower CMS payments, readmissions, and mortality. Furthermore, the majority of Medicare THAs in the United States are performed by surgeons who perform > 10 CMS operations annually. Compared with previous work, these results suggest a trend toward higher volume surgeons in the Medicare population. The results also suggest a benefit to the shift toward higher volume surgeons in reducing payments, readmissions, and mortality for elective THA in the United States. However, given that payments, readmission, and mortality of surgeons varied widely, it is important to note that available individual CMS data can be used to directly evaluate each individual surgeon based on their actual results well as through association with volume. Level of Evidence Level III, therapeutic study.
Introduction
Because surgeons and hospitals are now assuming financial risk and outcome responsibility in a value-based care environment, it is important to identify factors associated with both procedure outcomes and procedure expense.
Many studies have identified an association between low surgeon volume and higher complication rates after total joint arthroplasty [10, 12, 14, 16, [19] [20] [21] [22] ; however, an analysis of 1996 Medicare data showed that 52% of THAs in the United States were performed by lowvolume surgeons [9] . More recent data have shown that hospital volume of THA is also related to improved risk standardized complication rates and that there may be a trend toward increased use of higher volume hospitals [8, 11] , but it is not known whether there has been a similar trend toward higher volume surgeons. To our knowledge, no prior study has correlated comprehensive Medicare Payments, readmissions, and mortality after THA with surgeon volume.
Study Questions
(1) Is there an association between surgeon THA volume and 90-day Centers for Medicare & Medicaid Services (CMS) Part A payments, readmissions, or mortality? (2) What proportion of THAs in the United States is performed by low-and high-volume surgeons?
Materials and Methods
We performed a retrospective analysis on the CMS Limited Data Set (LDS) of all primary elective THAs performed in the United States (except Maryland) between January 2013 and June 2016 on patients insured by Medicare. In the LDS data, each beneficiary is assigned an anonymous unique identifier, which enables the attribution of CMS cost associated with each surgery episode through a 90-day postdischarge period. Maryland was excluded from this study because it is excluded from the CMS LDS because that state operates an all-payer rate-setting system independent of the national Medicare payment system [5] .
Software applications (Archway Health Advisors, Watertown, MA, USA) were developed to identify each elective THA. All expenditures from the date of surgery through 90 days after discharge were calculated, and each patient's demographics, geographic region of surgery, diagnosis codes, admission type, readmissions, and mortality were determined for each episode. All incomplete data points such as episodes without an associated hospital and episodes without coded demographics were excluded from the data. Finally, the data were restricted to elective hip arthroplasty coded as Total Joint Arthroplasty without Major Co-morbidity (Diagnosis-related Group [DRG] 470). After removing incompletely coded episodes, there were 630,449 Medicare THA episodes over the study period. Of those THAs, 422,814 were elective procedures. Of those elective THAs, 409,844 were DRG 470, the final analysis population for this study. CMS expenditures associated with these episodes totaled more than USD 7.7 billion in adjusted January 2013 dollars.
Each episode was associated with the operating surgeon's national provider identifier. The surgeons were categorized into five groups based on the annualized number of Medicare THAs they performed in the study period: highest volume (> 50), high volume (26-50), moderate volume (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , low volume (6-10), and lowest volume (1) (2) (3) (4) (5) . These cutoffs were chosen to align with the methodology of Katz et al. [9] .
We calculated all CMS Part A payments in the LDS data from the inpatient stay through the 90th day after discharge. CMS Part A includes the subcategories of inpatient stay, home health, skilled nursing, inpatient rehabilitation facility, long-term care hospital, outpatient, and readmission payments [3] . CMS Part B payments, including clinical research, ambulance services, durable medical equipment, mental health, doctor services, and limited outpatient prescription drugs, were not assessed [4] . We adjusted the Part A payments for inflation to first quarter 2013 dollars according to CMS Bundled Payments for Care Improvement trend factors for DRG 470. Furthermore, to account for geographic variations in payments, we normalized payments for each CMS core-based statistical area and each type of payment category according to Medicare final rules for each year and payment type [23] . Readmission and mortality were also gathered from the data set for each individual case. This methodology allowed for standardization of actual payments across years as well as between hospitals and geographic regions. The selection of the CMS data set allowed for a multiyear analysis of CMS total joint arthroplasties in the United States, which represent approximately 60% of joint replacements in the United States [12, 13] . It also enabled the identification of patient-specific factors (eg, age, sex, race, comorbidities) to control for confounding variables that may affect payments.
Each episode was analyzed for the CMS-provided comorbidity diagnosis codes. We categorized the diagnosis codes according to Elixhauser comorbidities [6] using the Enhanced International Classification of Diseases (ICD), 9 th Revision and Enhanced ICD, 10 th Revision categorization and methodology as described by Quan et al. [20] . The total number of comorbidities was calculated for each episode.
The adjusted payments data were transformed by natural log and the top 0.01% of procedures by payment were removed to better approximate normality. A logtransformed linear regression model was built for adjusted payments and controlled for age, sex, race, comorbidities, inflation, and geographic variation in spend. Logistic regression models were created for 90-day readmission and mortality and adjusted for the same factors. Statistical significance was calculated using the Student's t-test associated with the linear regression and z-test for odds ratios (ORs) associated with logistic regression. Statistical differences were assessed from regression performed using STATA IC version 15.0 (StataCorp LLC, College Station, TX, USA). The level of significance was set at p < 0.05.
Results

Payments, Readmissions, and Mortality by Surgeon Volume
Whereas little variability occurred in the acute hospital inpatient payments, variability of postacute care charges, especially skilled nursing facility charges, was dramatic (Fig. 1) . After controlling for available confounding variables including age, sex, comorbidities, ethnicity, elective surgical procedures, regional variation in payments, and inflation of hip surgery cost, payments per episode, readmissions, and mortality increased in a stepwise fashion as surgeon volume decreased (Fig. 2) . Compared with the highest volume surgeons, payments for high-volume surgeons were 5.4% higher (p < 0.001; 95% confidence interval [CI], 5.0%-5.7%), payments for moderate-volume surgeons were 12.8% higher (p < 0.001; 95% CI, 12.4%-13.2%), payments for low-volume surgeons were 20.4% higher (p < 0.001; 95% CI, 19.9%-20.9%), and payments for the lowest volume surgeons were 27.2% higher (p < 0.001; 95% CI, 26.6%-27.8%) (Fig. 3) . Readmission rates also increased during the first 90 days after discharge as surgeon volume decreased when controlling for the same factors. Compared with the highest volume surgeons, the OR for readmission in the first 90 days after discharge was 1.1 for high-volume surgeons (p < 0.001; 95% CI, 1.1-1.2), 1.3 for moderate-volume surgeons (p < 0.001; 95% CI, 1.3-1.4), 1.5 for low-volume surgeons (p < 0.001; 95% CI, 1.5-1.6), and 1.8 for the lowest volume surgeons (p < 0.001; 95% CI, 1.7-1.9) (Fig. 4) .
When controlling for the same factors, mortality also increased as surgeon volume decreased. Compared with the highest volume surgeons, the OR for mortality in the first 90 days after discharge was 1.5 for high-volume surgeons (p < 0.001; 95% CI, 1.3-1.8), 2.1 for moderate-volume surgeons (p < 0.001; 95% CI, 1.8-2.4), 2.9 for low-volume surgeons (p < 0.001; 95% CI, 2.5-3.4), and 4.7 for the lowest volume surgeons (p < 0.001; 95% CI, 4.0-5.5) (Fig. 5) .
Proportion of Procedures Performed by Higher Volume Surgeons
In terms of volume, the highest volume surgeons performed 98,080 (24%) of the operations, high-volume surgeons performed 110,915 (27%) of the operations, moderate-volume surgeons performed 112,670 (27%) of the operations, low-volume surgeons performed 50,179 (12%) of the operations, and low-volume surgeons performed 38,000 (9%) of the operations (Table 1) . There is wide variation in annual CMS THA volume and performance within the groups, and although the association described holds true, some individual surgeons in lower volume groups outperform the highest volume surgeons in terms of average payments, readmissions, and mortality (Fig. 6 ).
Discussion
Higher volume hip surgeons had lower postoperative payments, readmissions, and mortality after elective THA (DRG 470) than patients of low-volume hip surgeons, even when controlling for age, sex, comorbidities, ethnicity, elective surgical procedures, regional variation in costs, and inflation. The findings in this study corroborate other studies that found volume is related to complication rates [9, 14, 16, 21, 22, 24] and builds on those by identifying that higher volume surgeons are also associated with lower Medicare payments than low-volume surgeons. Furthermore, this study shows that these associations persist in a 3.5-year national Medicare data set even when restricting the data to elective, DRG 470 THAs and controlling for This study has several limitations. The analysis is limited to patients in the CMS LDS for a 3.5-year period who had elective THA without major medical comorbidities (DRG 470) and does not reflect the surgeon's years of experience or overall volume including non-CMS patients. Given that Medicare patients account for nearly 60% of all total joint arthroplasties [12, 13] , we believe that this data set is representative of most primary, elective THAs performed in the United States. The study also does not account for additional surgeon factors such as the volume of the hospital in which the surgeon operates, the practice type, or location. Previous studies have identified a relationship between hospital volume and complication rates, and it is possible that there is an association between hospital and surgeon volume. We believe that the association of volume in individual surgeons is critical to understand in addition to the hospital setting. Additionally, the data set includes only Medicare Part A and not Part B expenditures as a result of availability; we did not analyze increased or decreased use of physician services for these procedures. However, we believe that the benefits of large-scale standardized data afforded by the LDS outweigh the costs for studying nationwide trends in Medicare THA. Finally, the study did not include functional outcomes, patient satisfaction, and long-term revision rates, because they were not included in the administrative CMS data set and so cannot account for long-term or subjective outcomes. It is not surprising that patients treated by high-volume surgeons are associated with lower payments and more favorable readmission rates and mortality rates. The finding that low procedural volume is predictive of higher payments and increased complication rate has been reported in other studies for joint replacement and other common and higher risk procedures [1, 9, 12, [14] [15] [16] 19] . However, the quantification of improvement in payments, readmission, and mortality in this study is dramatic, especially when considering that only elective THAs without major complications were included in the analysis, and great care was taken to control for many factors that could influence outcome (such as patient comorbidities, age, and demographics). The finding that there is a mortality OR of 4.69 in the lowest volume group compared with the highest volume group is perhaps the most important.
Although statistical analysis was not performed on subgroups of Medicare Part A payments, the major drivers of savings for the higher volume surgeons appear to be those of skilled nursing facilities (USD 2371 versus USD 5535 in the highest volume versus lowest volume surgeon groups) and inpatient rehabilitation facilities (USD 558 versus USD 1640 in the highest volume versus lowest volume surgeon groups). These variations in postacute care are consistent with recent trends in bundled care programs showing that skilled nursing facility pay is a major modifiable component of cost [2, 17] and one of the largest drivers in geographic variation of Medicare payments [18] . Additional analysis should be undertaken to elucidate how savings are achieved by low-cost surgeons without sacrificing outcomes.
Although there is a clear association among surgeon volume, payments, readmissions, and mortality, the current availability of CMS data on individual surgeons allows for identification of higher-quality, lower-cost surgeons directly. In addition to identifying the general associations with higher volume, this study also shows that there is wide variation in outcomes, and some lower-volume surgeons outperform the top-volume surgeons (Fig. 6 ). This may be the result of highly experienced surgeons with lower volume or effects of smaller sample sizes. Nevertheless, the wealth of available performance data for each individual surgeon obviates the need to categorize surgeons' practice patterns based on volume alone, as has been suggested previously [24] , and current policies should be reconsidered [7] . Similar analytics can be performed on a hospitalor surgeon-specific basis to more accurately identify predictors of desirable outcomes.
Most THAs in patients insured by Medicare in the United States are performed by moderate-to high-volume surgeons. Patients cared for by higher-volume surgeons had a lower risk of readmission, a lower risk of death, and the care of those patients was associated with lower CMS Part A payments. These data suggest that surgeons specializing in high volumes of a specific operation may achieve improvements in reducing payments and outcomes. Sharing of best practices between high-and low-performing surgeons and hospitals may also improve outcomes on a larger scale. As hospitals and surgeons strive for improvement in cost and outcomes in the new environment of value-based care, surgeon-and hospital-specific actual data should be further analyzed to identify areas for improvement.
